We are delighted to report that this month we received full regulatory approval to start our Phase 2 trial in adults with newly diagnosed pulmonary tuberculosis (TB). The study will be conducted at the TASK Clinical Research Centre in Cape Town, SA and will evaluate the safety, tolerability, and efficacy of our lead anti-microbial, respiratory asset, RESP301.
RESP301 significantly reduces Mycobacterium tuberculosis (M.tb) in vitro so we are excited to see whether this result can be replicated in the clinic. If the initial phase of the study is successful, and bactericidal activity is observed against M.tb, we will then advance the program to investigate the efficacy of RESP301 in combination with standard of care, oral therapy.
Dr Syed Jafri, Chief Medical Officer, 30 Technology
“This is a significant milestone for the 30 Respiratory team. The Principal Investigator, Prof Diacon, is a world-renowned expert in researching new TB therapeutics, and we are really pleased to be collaborating with him on this key study. We eagerly await the initial readout in Q2 2024 and longer-term we are confident that our novel therapy has the potential to be a game-changer for treating newly diagnosed TB patients worldwide”.